These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 37197442)

  • 61. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
    Sharma R; Pillai A; Marron TU; Fessas P; Saeed A; Jun T; Dharmapuri S; Szafron D; Naqash AR; Gampa A; Wang Y; Khan U; Muzaffar M; Lee CJ; Lee PC; Bulumulle A; Paul S; Bettinger D; Hildebrand H; Yehia M; Pressiani T; Kaseb A; Huang YH; Ang C; Kudo M; Nishida N; Personeni N; Rimassa L; Pinato DJ
    Hepatol Commun; 2022 Jul; 6(7):1776-1785. PubMed ID: 35481940
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
    Zhang L; Chen C; Chai D; Li C; Guan Y; Liu L; Kuang T; Deng W; Wang W
    Front Immunol; 2022; 13():956533. PubMed ID: 36059512
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
    Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discontinuation of immune checkpoint inhibitors in hepatocellular carcinoma: a retrospective cohort study.
    Zhou L; Zhang Y; Zheng J; Ruan M; Zhang J; Li Y; Jin R; Wu D; Sun H; Zhang J; Wang R
    J Gastrointest Oncol; 2024 Aug; 15(4):1698-1711. PubMed ID: 39279966
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis.
    Huang L; Chen X; Zhou L; Xu Q; Xie J; Zhan P; Lv T; Song Y
    Ann Palliat Med; 2021 Mar; 10(3):2709-2722. PubMed ID: 33549013
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
    Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
    JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
    Tinsley N; Zhou C; Tan G; Rack S; Lorigan P; Blackhall F; Krebs M; Carter L; Thistlethwaite F; Graham D; Cook N
    Oncologist; 2020 Jan; 25(1):55-63. PubMed ID: 31292268
    [TBL] [Abstract][Full Text] [Related]  

  • 68. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
    Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
    J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
    Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma.
    Alshammari K; Alotaibi FM; Alsugheir F; Aldawoud M; Alolayan A; Algarni MA; Sabatin F; Mohammad MF; Alosaimi A; Sanai FM; Odah H; Alshehri AS; Aldibasi OS; Alrehaily S; Al Saleh AS
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201560
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
    Mohiuddin JJ; Chu B; Facciabene A; Poirier K; Wang X; Doucette A; Zheng C; Xu W; Anstadt EJ; Amaravadi RK; Karakousis GC; Mitchell TC; Huang AC; Shabason JE; Lin A; Swisher-McClure S; Maity A; Schuchter LM; Lukens JN
    J Natl Cancer Inst; 2021 Feb; 113(2):162-170. PubMed ID: 32294209
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Jun; 138(6):1591-1599. PubMed ID: 36308485
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
    Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
    Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    Rezaee-Zavareh MS; Yeo YH; Wang T; Guo Z; Tabrizian P; Ward SC; Barakat F; Hassanein TI; Dave S; Ajmera V; Bhoori S; Mazzaferro V; Chascsa DMH; Liu MC; Aby ES; Lake JR; Sogbe M; Sangro B; Abdelrahim M; Esmail A; Schmiderer A; Chouik Y; Rudolph M; Sohal D; Giudicelli H; Allaire M; Akce M; Guadagno J; Tow CY; Massoumi H; De Simone P; Kang E; Gartrell RD; Martinez M; Paz-Fumagalli R; Toskich BB; Tran NH; Solino GA; Poltronieri Pacheco DM; Kalman RS; Agopian VG; Mehta N; Parikh ND; Singal AG; Yang JD
    J Hepatol; 2025 Jan; 82(1):107-119. PubMed ID: 38996924
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors.
    Lei J; Yan T; Zhang L; Chen B; Cheng J; Gao X; Liu Z; Li Y; Zuo S; Lu Y
    Hepatol Int; 2023 Apr; 17(2):281-290. PubMed ID: 36580258
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Ohkawa K; Oshita M; Miyazaki M; Yakushijin T; Nozaki Y; Matsumoto K; Tanaka S; Kaneko A; Iio S; Nawa T; Yamada Y; Morishita N; Usui T; Hiramatsu N; Doi Y; Sakakibara M; Imanaka K; Yoshida Y; Kodama T; Hikita H; Tatsumi T; Takehara T
    PLoS One; 2023; 18(2):e0281459. PubMed ID: 36749777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
    Balcar L; Scheiner B; Fulgenzi CAM; D'Alessio A; Pomej K; Roig MB; Meyer EL; Che J; Nishida N; Lee PC; Wu L; Ang C; Krall A; Saeed A; Stefanini B; Cammarota A; Pressiani T; Abugabal YI; Chamseddine S; Wietharn B; Parisi A; Huang YH; Phen S; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; von Felden J; Schulze K; Silletta M; Trauner M; Samson A; Wege H; Piscaglia F; Galle PR; Stauber R; Kudo M; Singal AG; Itani A; Ulahannan SV; Parikh ND; Cortellini A; Kaseb A; Rimassa L; Chon HJ; Pinato DJ; Pinter M
    JHEP Rep; 2024 Feb; 6(2):100982. PubMed ID: 38274490
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
    Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.